BACKGROUND
-Ulipristal acetate 5mg (Esmya®) is a Selective Progesterone Receptor Modulator indicated for the preoperative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. -The aim of this analysis was to assess the cost-effectiveness of ulipristal acetate 5 mg as a 3-month add-on therapy to standard pre-surgical observation and immadiate hysterectomy in Romanian health care settings.
METHODS
-A decision-analytic Markov cohort model was developed over a 10-year time horizon. Ulipristal acetate was compared with pre-surgical observation and immediate hysterectomy. The analysis was performed from the public payer perspective in Romania. -The model comprised the following mutually exclusive health states: no or mild bleeding disorder, heavy bleeding disorder, persistent heavy bleeding disorder, myomectomy, post-myomectomy with no or mild bleeding disorder, post-myomectomy with heavy bleeding disorder, hysterectomy, post-hysterectomy, menopause and death. Patient pathways followed the pattern of the Pearl I clinical trial (Donnez et al., 2012) . Bleeding was measured by Pictorial Blood Assessment Chart (PBAC) score over 28 days. 'No or mild bleeding' was defined as patients with PBAC < 225 during 28 days, whereas 'heavy bleeding' was defined as patients with PBAC ≥ 225 during 28 days. Patient started the model with heavy bleeding (Nagy et al., 2014) .
Patient pathways of the model are shown in Figure 1 . -Transition probabilities were calculated based on the Pearl I clinical trial data (Donnez et al., 2012) , a scientific paper (Hirst et al., 2008) , and results of the International Esmya® Expert Panel meeting. Transition probabilities of the first 3 model cycles for the ulipristal acetate and pre-surgical observation arms are summarized in Table 1 . After the third cycle, the transition probabilities were assumed to be equal on both arms. Table 2 . -Utility values were determined applying data from Pearl II trial (Preglem, 2010) and the scientific literature (WHO, 2004; Wodlin, 2011a; Wodlin, 2011b) . The Pearl II trial measured the patient quality of life using the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire. UFS-QOL results were transformed into EQ-5D index score using Rowen and Brazier mapping algorithm (Rowen and Brazier, 2011) . No difference was assumed between the utility of myomectomy and hysterectomy, similar to the NICE HOPEFUL study (Hirst et al., 2008) . For women who underwent hysterectomy, the diminishing symptoms of uterine fibroids had a positive impact on utility compared with the severe excessive bleeding symptoms, whereas the loss of fertility and other psychological problems had a negative impact compared with 'no or mild bleeding'. Therefore, the utility after hysterectomy was assumed to be smaller in the state of 'no or mild bleeding'. The quality of life gain after hysterectomy was reduced by the disutility due to infertility (-0.18). Table 3 summarizes the utility values applied in the cost-effectiveness model. -The starting age of the cohort was assumed to be 42 years, similar to the mean age of the patients in the Pearl I trial ( (Donnez et al., 2012) . In addition, 50 years was assumed to be the mean age of the patients at menopause. -Costs and benefits were discounted on a yearly rate of 3.5%.
CONCLUSIONS
-The results of this analysis suggest that adding ulipristal acetate treatment to standard pre-surgical therapy represents a good value for money in Romania (threshold: 19,914 EUR/QALY). Comparison to immediate hysterectomy (the standard procedure in several jurisdictions, which cannot be considered as base case comparator in our analysis, because of missing clinical trial data) significantly reduces the cost effectiveness ratio. -Ulipristal acetate is viewed as an important treatment alternative for patients who seek to preserve their fertility or postpone surgical intervention. Based on the available evidence the current model focuses on short term benefits only (i.e. short term consequences of less heavy bleeding), however additional scientific evidence on potential long term benefits (preserved fertility, avoidance of surgery) may further increase the economic value of Esyma® therapy. 
RESULTS
-Adding a 3-month course of ulipristal acetate to pre-operative observation was predicted to achieve an additional 0.021 quality-adjusted life years (QALYs) at an estimated incremental cost of 292 EUR, which would result in an incremental cost-effectiveness ratio of 13,870 EUR/QALY (Table 4) . When 3 months of ulipristal acetate therapy was compared with immediate hysterectomy, the incremental cost-effectiveness ratio was reduced to 1,818 EUR/QALY (Table 5 ). -Deterministic sensitivity analyses were run with model variables. Results were robust to changes in most model parameters, except for utility values of post-hysterectomy and no/mild bleeding ( Figure 2 ). 
